Therapie von klimakterischen Symptomen bei Patientinnen nach frühem Mammakarzinom

Kernaussagen

Das Mammakarzinom ist die häufigste Malignomerkrankung der Frau. Die überwiegende Anzahl der Patientinnen ist postmenopausal. Die Therapie klimakterischer Beschwerden bei Patientinnen mit Mammakarzinom ist eine Herausforderung für den Arzt. Die adjuvante endokrine Therapie verbessert das Überleben der Patientin mit Mammakarzinom. Therapiebedingte Nebenwirkungen können die Lebensqualität beeinflussen. Das Mammakarzinom exprimiert Steroidhormonrezeptoren. Dies macht den Einsatz von Sexualsteroiden nicht unbedenklich. Im Vordergrund steht das therapiebedingte erhöhte Rezidivrisiko. Daher ist der Einsatz einer Hormontherapie mit Östrogenen ggf. in Kombination mit Gestagenen (HT) bei Patientinnen mit frühem Brustkrebs nur in ausgewählten Fällen möglich.

• Literatur

• 1 Levi F, Bosetti C, Lucchini F et al. Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev 2005; 14: 497-502
• 2 Murthy V, Chamberlain RS. Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control 2012; 19: 317-329
• 3 Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141
• 4 Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816
• 5 Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008; 107: 167-180
• 6 Stearns V, Hayes DF. Approach to menopausal symptoms in women with breast cancer. Curr Treat Options Oncol 2002; 3: 179-190
• 7 Ruhstaller T, von Moos R, Rufibach K et al. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 2009; 76: 142-148
• 8 Cella D, Fallowfield L, Barker P et al. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006; 100: 273-284
• 9 Amir E, Seruga B, Niraula S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103: 1299-1309
• 10 DiSaia PJ, Grosen EA, Kurosaki T et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174: 1494-1498
• 11 Col NF, Hirota LK, Orr RK et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001; 19: 2357-2363
• 12 Holmberg L, Iversen OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100: 475-482
• 13 von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97: 533-535
• 14 Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005; 6: 687-695
• 15 Kenemans P, Bundred NJ, Foidart JM et al. LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-146
• 16 Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womenʼs Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701-1712
• 17 Ortmann O, Pagani O, Jones A et al. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat Rev 2011; 37: 97-104
• 18 Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; (4) CD001500
• 19 Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-255
• 20 Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991; 14: 23-31
• 21 Weisberg E, Ayton R, Darling G et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005; 8: 83-92
• 22 Gerbaldo D, Ferraiolo A, Croce S et al. Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women. Maturitas 1991; 13: 269-274
• 23 Buhling KJ, Eydeler U, Borregaard S et al. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung 2012; 62: 378-383
• 24 Kendall A, Dowsett M, Folkerd E et al. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17: 584-587
• 25 Wills S, Ravipati A, Venuturumilli P et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012; 8: 144-148
• 26 Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6: 45-52
• 27 Griesser H, Skonietzki S, Fischer T et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012; 71: 360-368
• 28 Pfeiler G, Glatz C, Konigsberg R et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011; 14: 339-344
• 29 Biglia N, Peano E, Sgandurra P et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010; 26: 404-412
• 30 Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand 1983; 62: 393-396
• 31 Donders G, Neven P, Moegele M et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145: 371-379
• 32 Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. J Am Med Assoc 2006; 295: 2057-2071